Market Size and Overview:

In the year 2023, the Global Macrogol Laxative Market attained a valuation of $2.09 billion and is anticipated to achieve a market size of $2.61 billion by the year 2030. Throughout the envisaged period from 2024 to 2030, the market is expected to exhibit growth at a Compound Annual Growth Rate (CAGR) of 3.2%.

Market Overview:

Constipation is a prevalent condition with global ramifications, affecting the physical and emotional well-being of both adults and children. It is a distressing ailment impacting nearly 12% of the worldwide population, arising from factors such as insufficient dietary fiber, sedentary lifestyle, pregnancy, among others. Prolonged constipation can transition into a chronic and persistent state. The incidence of constipation ranges from 2.5% to 79% in adults and 0.7% to 29.6% in children. It is more common among individuals aged 60 and above, escalating with age, and exhibits higher frequency in lower-income groups. Factors like low-fiber diet, residing in densely populated areas, family history of constipation, and mental health issues contribute to its occurrence. Macrogol Laxative emerges as a safe and efficient treatment for constipation, employing mechanisms such as emollient, contact, bulk-forming, and osmotic actions. Its higher water content increases fecal mass, stimulating bowel movements and softening stools for ease of passage. Macrogol, administered at a comparatively lower dose, has demonstrated efficacy in improving stool frequency in chronic constipation without requiring dose escalation. While generally considered safe, some patients may experience side effects like diarrhea and bloating.

COVID-19 Impact on Macrogol Laxative Market:

The onset of the COVID-19 outbreak in Wuhan, China, in December 2019, rapidly spread globally, affecting numerous countries. China, Italy, Iran, Spain, the Republic of Korea, France, Germany, and the US experienced significant impacts in terms of positive cases and reported deaths. The pandemic disrupted economies and industries, including healthcare and pharmacy, with supply chain interruptions, technological events, and office closures. Lockdowns and lifestyle changes during the pandemic disrupted the colon's circadian rhythm due to reduced physical activity, unhealthy eating habits, and stress, leading to increased demand for constipation laxatives. However, disruptions in healthcare product delivery mechanisms worldwide hindered market growth. The US, a major manufacturing center for Macrogol Laxative, faced shutdowns, supply chain disruptions, and economic downturn, impacting overall market growth.

Market Drivers:

Growing demand for R&D and new technology in the Pharmaceutical Industry is propelling market growth:

Private capital investment and increased spending on pharmaceutical R&D, coupled with the approval and launch of new drugs, have surged in recent years. Drug R&D spending witnessed a nearly 65% rise between 2017 and 2020, driving constant innovations in the pharmacy industry and escalating the global Macrogol Laxatives market.

The increasing occurrence of eating disorders among people is driving demand for Macrogol Laxative:

Irregular bowel patterns due to unhealthy eating habits and sedentary lifestyles are on the rise, leading to a higher incidence of gastric diseases. This trend is expected to fuel market growth, supported by government initiatives promoting health awareness and laxative use.

Surging investments in the healthcare industry are fostering market growth:

Increased investments in healthcare infrastructure and government initiatives to enhance global healthcare status are contributing to market growth.

The growing geriatric population is boosting the demand for Macrogol Laxatives:

The rising geriatric population is a key driver, as bowel movement disorders become more prevalent with age. Macrogol laxatives are increasingly utilized by seniors, propelling market growth.

Market Restraints:

Patent expiration hindering market growth:

The global Macrogol Laxatives market faces declining profit margins due to the expiration of key patents, driven by an aging population and patent losses. Anticipated patent expirations of multi-billion-dollar brand drugs within the next few years pose a significant challenge, limiting market growth.

Macrogol Laxatives Market – By Drug Name:

• Movicol
• Casenlax
• VistaPrep
• CosmoCol
• Molaxole
• Endofalk
• Glycoprep
• Forlax
• Laxido
• MiraLAX
• Other Macrogols

The Macrogol Laxatives Market has been categorized into ten major drugs: Movicol, Casenlax, VistaPrep, CosmoCol, Molaxole, Endofalk, Glycoprep, Forlax, Laxido, and MiraLAX, based on the drug names.

Macrogol Laxatives Market – By Diseases:

• Inflammatory Bowel Diseases (IBD)
• Irritable Bowel Syndrome (IBS)
• Drug Induced Constipation (DIC)
• Other

The market is segmented into three major disease categories for which it may be used: Inflammatory Bowel Diseases (IBD), Irritable Bowel Syndrome (IBS), and Drug-Induced Constipation (DIC).

The Inflammatory Bowel Diseases segment dominates the market, with laxatives also prescribed for individuals with irritable bowel syndrome.

Macrogol Laxatives Market – By Age Group:

• Baby Boomers and Older
• Generation X
• Millennials
• Generation Z
• Generation Alpha

Segmented into five categories – Baby Boomers and Older, Generation X, Millennials, Generation Z, and Generation Alpha – the adult segment holds prominence in the global Macrogol Laxatives market. The increasing prevalence of stool disorders among adults due to poor dietary habits contributes to the market's growth.

Macrogol Laxatives Market - By Administration Route:

• Oral
• Nasogastric
• Ophthalmic
• Topical

Categorized into four segments – Oral, Nasogastric, Ophthalmic, and Topical – the oral drugs segment dominates the market. Oral laxatives, taken by mouth, facilitate smooth bowel movements to alleviate constipation, while rectal laxatives are commonly used for children.

Macrogol Laxatives Market – By Distribution Channel:

• Direct Sales
• Whole Sales
• Others

The market is segmented into three categories – Direct Sales, Whole Sales, and Others. The direct sales segment holds a significant share in terms of revenue, as these laxatives are available over the counter, facilitating easy access for individuals experiencing digestive discomfort.

Macrogol Laxatives Market – By Region:

• North America
• Europe
• Asia-Pacific
• South America
• Middle-East and Africa

The market is divided into five major regions – North America, Europe, Asia-Pacific, South America, and the Middle-East and Africa. North America leads with a 38% revenue share, attributed to the rapid increase in awareness of gastric diseases among the population.

Macrogol Laxatives Market – By Companies:

• Abbott Laboratories 
• AstraZeneca, Bayer
• Boehringer Ingelheim
• Braintree Laboratories 
• GlaxoSmithKline 
• Procter & Gamble Company 
• Purdue Pharma
• Sucampo Pharmaceuticals
• Takeda Pharmaceutical Company

Recent Industry Developments:

In March 2021, Purdue Pharma L.P. announced the launch of two products, namely Senokot Laxative Gummies – Blueberry Pomegranate and Senokot Tea, for the treatment of constipation.